Company News

You are here:

Home
News

PharmaJet selected to deliver Scancell COVID-19 DNA Vaccine

GOLDEN, Colo. — September 14, 2021 - PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its partner, Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis^® and PharmaJet Stratis^® Needle-free Injection Systems.

Scancell’s COVIDITY-001 study, including the use of the two PharmaJet systems, has been approved by the South African regulatory authority. This program is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University.

Details

PharmaJet partner Zydus Cadila announces Emergency Use Authorization approval for world’s first plasmid DNA COVID-19 vaccine

GOLDEN, Colo. — August 23, 2021 - PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine, ZyCoV-D, is exclusively administered using the PharmaJet Tropis^® Needle-free Injection System. Details

PharmaJet partner Zydus Cadila seeks EUA on world’s first plasmid DNA COVID-19 vaccine

GOLDEN, Colo. — July 7, 2021 - PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19. The vaccine, ZyCoV-D, will be exclusively administered using the PharmaJet Tropis^® Needle-free Injection System. Zydus Cadila is a global pharmaceutical company based in India, that develops, manufactures, and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines. Details

Update: PharmaJet Needle-free COVID-19 Vaccine Trial

GOLDEN, Colo. — June 30, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2. COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with and Melbourne-based biotech Technovalia. The PharmaJet System was chosen due to its record of increasing the effectiveness of DNA vaccines, ease-of-use, and speed of the delivery system compared to traditional needle and syringe. Details

PharmaJet Announces Addition of Paul LaBarre as VP Global Business Development

GOLDEN, Colo. — June 15, 2021 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Paul LaBarre, has joined the leadership team as Vice President, Global Business Development. Mr. LaBarre is a global business executive with over 20 years of global health experience across the innovation value chain including strategy, research, product development, and strategic business development, most notably with UNICEF and PATH. In this role he will be leading business development and commercialization strategies for the PharmaJet organization replacing Melissa Malhame who transitioned to a strategic advisory role for the company. Details

The Lancet Publication Confirms Viability of Intradermal Polio Vaccination

GOLDEN, Colo. — June 3, 2021- A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV). Previous studies have shown that two doses of intradermally-delivered IPV (60% less vaccine) were more immunogenic than one full dose delivered intramuscularly. Intradermal fractional dose delivery also lowers the total cost of vaccination substantially. Details

PharmaJet presents Needle-free delivery of Covid-19 DNA vaccine results at World Vaccine Congress

GOLDEN, Colo. — April 27, 2021 — PharmaJet^®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the World Vaccine Congress on May 6. The presentation, entitled Progress of COVID-19 Vaccines with Needle-Free Delivery, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc. Details

Global NGO expands use of PharmaJet for Polio Eradication Campaigns

GOLDEN, Colo. — March 9, 2021 — PharmaJet ^® , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis^® Needle-free Injection System in polio eradication campaigns. The latest country addition, Somalia, adds to the already successful vaccination programs in Pakistan, Cuba, The Gambia and others.

Details

PharmaJet Announces Appointment of Marian Wentworth to Board of Directors

GOLDEN, Colo. — February 9, 2021 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that Marian Wentworth has been appointed to its Board of Directors. Ms. Wentworth, President and CEO of Management Sciences for Health, is an accomplished global health executive with extensive experience in global strategy, innovation, and development. Details

PharmaJet and Diomics partner on SARS-CoV-2 immune response monitoring

GOLDEN, Colo. — November 17, 2020 — PharmaJet^®, the maker of innovative, needle-free injection technology, today announced that its Tropis^® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck^™ system and is expected to begin human clinical trials in December 2020. Details